Heron Therapeutics (HRTX) Convertible Debt (2011 - 2026)
Heron Therapeutics' (HRTX) quarterly Convertible Debt came in at $33.3 million in Q1 2026, down 77.75% YoY from $149.8 million in Q1 2025, and up 1.8% on a QoQ basis from $32.7 million in Q4 2025.
Heron Therapeutics (HRTX) Convertible Debt (2011 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 7 years of Convertible Debt data on file, last reported at $33.3 million in Q1 2026.
- Quarterly Convertible Debt fell 77.75% year-over-year to $33.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.3 million (down 77.75% YoY) and the FY2025 annual result came in at $32.7 million, down 78.13% from the prior year.
- Convertible Debt advanced to $33.3 million in Q1 2026, from $32.7 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $149.8 million in Q1 2025 to a low of $32.2 million in Q3 2025.
- A 5-year average of $127.6 million and a median of $149.4 million in 2023 frame the typical range for Convertible Debt.
- The widest YoY moves for Convertible Debt: up 0.14% in 2025, down 78.5% in 2025.
- Tracing HRTX's Convertible Debt over 5 years: stood at $149.3 million in 2022, then increased by 0.14% to $149.5 million in 2023, then climbed by 0.14% to $149.7 million in 2024, then tumbled by 78.13% to $32.7 million in 2025, then climbed by 1.8% to $33.3 million in 2026.
- The last three Convertible Debt figures came in at $33.3 million (Q1 2026), $32.7 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.93 Mn |
| Mar 31, 2026 | 33.33 Mn |
| Dec 31, 2025 | 32.74 Mn |
| Sep 30, 2025 | 32.18 Mn |
| Mar 31, 2025 | 149.75 Mn |
| Dec 31, 2024 | 149.70 Mn |
| Sep 30, 2024 | 149.65 Mn |
| Jun 30, 2024 | 149.60 Mn |
| Mar 31, 2024 | 149.54 Mn |
| Dec 31, 2023 | 149.49 Mn |
| Sep 30, 2023 | 149.44 Mn |
| Jun 30, 2023 | 149.39 Mn |
| Mar 31, 2023 | 149.34 Mn |
| Dec 31, 2022 | 149.28 Mn |
| Sep 30, 2022 | 149.23 Mn |
| Jun 30, 2022 | 149.18 Mn |
| Mar 31, 2022 | 149.13 Mn |
| Dec 31, 2021 | 149.08 Mn |
| Sep 30, 2021 | 149.03 Mn |
| Jun 30, 2021 | 148.98 Mn |